SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-127517
Filing Date
2022-12-16
Accepted
2022-12-16 06:05:30
Documents
12
Period of Report
2022-12-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2232869d1_8k.htm   iXBRL 8-K 24522
  Complete submission text file 0001104659-22-127517.txt   199235

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA scps-20221215.xsd EX-101.SCH 3054
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20221215_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20221215_pre.xml EX-101.PRE 22609
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2232869d1_8k_htm.xml XML 3705
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39788 | Film No.: 221466368
SIC: 2834 Pharmaceutical Preparations